Figure S1. The screening flow chart

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Endpoint	Aspirin group(n=1641)	Combination group(n=1420)	*p*
eGFR decline	435(26.51%)	242(17.04%)	<0.001*
eGFR mild decline	338(20.60%)	178(12.54%)	
eGFR severe decline	97(5.91%)	64(4.51%)	
AKI(AKIN stage ≥1)	159(9.69%)	76(5.35%)	<0.001*
Stage 1 AKI	143(8.71%)	55(3.87%)	
Stage 2 AKI	9(0.55%)	11(0.77%)	
Stage 3 AKI	7(0.43%)	10(0.70%)	

Table S1. Incidence of AKI and eGFR decline in patients before matching
*p <0.05.

Variable	OR	Lower 95%CI	Upper 95%CI	*p*
Sex (male)	1.035	0.782	1.369	0.811
Age (years)	1.021	1.008	1.034	0.001*
Uric acid (μmol/L)	1.002	1.001	1.003	0.001*
BUN (mmol/L)	1.147	1.116	1.179	0.000*
Baseline creatinine (μmol/L)	1.009	1.007	1.010	0.000*
Hematokrit (%)	0.923	0.903	0.942	0.000*
Hypertension	1.400	0.966	2.028	0.076
Diabetes	1.761	1.348	2.300	0.000*
Angina	0.696	0.424	1.142	0.151
Myocardial infarction	2.255	1.601	3.177	0.000*
Heart failure	3.244	2.328	4.520	0.000*
Anemia	2.351	1.792	3.083	0.000*
CKD	3.349	2.548	4.401	0.000*
Contrast agents	0.875	0.626	1.222	0.434
Diuretic	4.604	3.495	6.065	0.000*
ACEI	1.071	0.775	1.480	0.677
ARB	1.403	1.006	1.958	0.046*
Calcium antagonists	1.402	1.074	1.831	0.013*
β-blocker	1.071	0.775	1.480	0.677
Cephalosporin	1.533	1.128	2.083	0.006*
Statins	0.906	0.668	1.227	0.523

Table S2. Univariate logistic regression analysis for risk factors of AKI before matching

Abbreviations: BUN, blood uric nitrogen; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor inhibitor. OR, odds ratio; 95%CI, confdence interval.

*p <0.05.

Baseline eGFR	AKIN stage	Aspirin group	Combination group	*p*
eGFR<30mL/		N=63(%)	N=68(%)	
(min1.73 m^2)	AKI (Stage ≥1)	14(22.22%)	19(27.94%)	0.451
				0.463
	0	49(77.78%)	49(72.06%)	
	Stage 1	13(20.63%)	18(26.47%)	
	Stage 2	0	0	
	Stage 3	1(1.59%)	1(1.47%)	
30≤ eGFR		N=264(%)	N=238(%)	
<60mL/	AKI (Stage ≥1)	26(9.85%)	18(7.56%)	0.366
(min1.73 m^2)				0.417
	0	238(90.15%)	220(92.44%)	
	Stage 1	24(9.09%)	11(4.62%)	
	Stage 2	1(0.38%)	4(1.68%%)	
	Stage 3	1(0.38%)	3(1.26%)	
60≤ eGFR		N=391(%)	N=389(%)	
<90mL/	AKI (Stage ≥1)	29(7.42%)	17(4.37%)	0.071
(min1.73 m^2)				0.077
	0	362(92.58%)	372(95.63%)	
	Stage 1	24(6.14%)	11(2.83%)	
	Stage 2	3(0.77%)	3(0.77%)	
	Stage 3	2(0.51%)	3(0.77%)	
90≤eGFRmL/		N=268(%)	N=291(%)	
(min1.73 m^2)	AKI (Stage ≥1)	7(2.61%)	8(2.75%)	0.920
				0.913
	0	261(97.39%)	283(97.25%)	

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Stage 1	4(1.49%)	4(1.37%)
Stage 2	3(1.12%)	2(0.69%)
Stage 3	0	2(0.69%)

Table S3.Incidence of different stages AKI in diffenrent baseline eGFR groups between the two therapies.

*p <0.05.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Baseline eGFR	eGFR decline	Aspirin group	Combination group	p
<30mL/ (min1.73 m^2)		N=63(%）	N=68(%)	
	decline	15(23.81%)	21(30.88%)	0.365
				0.309
	0	48(76.19%)	47(69.12%)	
	mild decline	12(19.05%)	14(20.59%)	
	severe decline	3(4.76%)	7(10.29%)	
30≤ eGFR <60mL/ (min1.73 m^2)		N=264(%)	N=238(%)	
	decline	52(19.70%)	30(12.61%)	0.032*
				0.040
	0	212(80.30%)	208(87.39%)	
	mild decline	39(14.77%)	19(7.98%)	
	severe decline	13(4.92%)	11(4.62%)	
60≤ eGFR <90mL/ (min1.73 m^2)		N=391(%)	N=389(%)	
	decline	79(20.20%)	40(10.28%)	0.000*
				0.000
	0	312(79.80%)	349(89.72%)	
	mild decline	57(14.58%)	26(6.68%)	
	severe decline	22(5.63%)	14(3.60%)	
90≤eGFRmL/ (min1.73 m^2)		N=268(%)	N=291(%)	
	decline	98(36.57%)	76(26.12%)	0.008*
				0.009
	0	170(63.43%)	215(73.88%)	
	mild decline	82(30.60%)	63(21.65%)	
	severe decline	16(5.97%)	13(4.47%)	

Table S4.Incidence of eGFR decline in diffenrent baseline eGFR groups between the two

6

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

therapies.

eGFR decline: eGFR decreased >10% from baseline eGFR; mild decline: decreased 10%-30% from baseline eGFR; severe decline: decreased >30% from baseline eGFR; eGFR didn't decrease or decreased ≤10%.

*p <0.05.